Professional Documents
Culture Documents
AETIOLOGY
Yellow fever virus (YFV) is an arboviral flavivirus (enveloped, positive-sense single-stranded RNA), and is
considered the “prototype” flavivirus. There is one serotype of YFV divided into three genotypes: I, IIA, and
IIB. YFV is maintained in non-human primate reservoirs and is transmitted by mosquitoes via urban and
sylvatic cycles. YFV is zoonotic and has been recognised in Central and South America as a significant cause
of disease in humans since the 1600s. This technical card focuses on disease in nonhuman primates unless
specifically stated.
EPIDEMIOLOGY
Hosts
Transmission
Sources
Occurrence
YFV is primarily found in Africa and Central and South America. There is concern regarding potential
establishment of YFV in Asia and North America due to the presence of presumed competent vector species.
In the Americas, many monkey populations are not large enough to sustain YFV at endemic levels. The virus
is referred to as a “wandering epidemic” because it slowly moves through large populations and returns to an
area once there are sufficient numbers of susceptible individuals. There have been several epizootics in Brazil.
In the Amazon, epizootics occur in a cyclical fashion in both humans and nonhuman primates approximately
every 7-14 years.
In Africa, YFV is maintained in primate populations in forest canopies, forest galleries, and savannahs. Many
Aedes species in Africa readily feed upon both humans and non-human primates.
DIAGNOSIS
Clinical disease in neotropical monkeys is generally more severe than in African primates. There is a 3-6
day incubation period.
Clinical diagnosis
Clinical signs in non-human primates include a sudden onset of fever, depression, vomiting, lumbosacral
pain, myalgia, and haemorrhage; however, many individuals can remain asymptomatic. After 3-4 days,
there may be subsequent resolution of clinical signs or development of biphasic, so-called “toxic” disease,
characterised by recurrent fever, bradycardia, conjunctival congestion, gingival haemorrhage, epistaxis,
haematemesis, epigastric pain, dehydration, and prostration. Gastrointestinal and uterine haemorrhage,
marked icterus, hepatic and renal failure, shock, convulsions, and death can occur in severe cases.
Lesions
Differential diagnoses
Laboratory diagnosis
Samples
● Peripheral blood
● Liver
○ Fresh tissue is more reliable for nucleic acid detection but formalin-fixed tissues may be
used if necessary
● There are data to support the use of semen and urine as diagnostic fluids in humans but has not
been proven in primates.
Serological tests
● Serum
● Whole blood
Procedures
● Histopathology is preferred when antemortem serum or blood is unavailable, when samples are not
suitable for genome detection or virus isolation, or when there is severe haemolysis or autolysis
● Virus isolation
● Reverse-transcriptase polymerase chain reaction (RT-PCR)
○ Avoid the use of assays specifically targeted towards vaccine strains
○ Choose assays targeted towards American and African strains as appropriate
● Antigen-capture enzyme linked immunosorbent assay (ELISA)
● Immunohistochemistry (IHC)
○ Kupffer cells, renal tubular epithelial cells, and myocardial fibers are particularly useful
Serological tests
● Antibody-capture ELISA
○ The presence of IgM in the absence of prior vaccination is strongly suggestive of infection,
but other flaviviruses must be ruled out
○ Serology is prone to cross-reactivity with other flaviviruses
● Paired acute and convalescent IgG titres
● Immunoperoxidase monolayer assay
● Indirect immunofluorescence
● Multiplex microsphere immunoassay (MIA)
● Plaque reduction neutralization assay (PRNT) or virus neutralization test (VNT)
○ Current gold standard assays
○ Requires multiple days to perform and may therefore not be well-suited to inform outbreak
responses
Sanitary prophylaxis
● Do not allow accumulation of standing water as these conditions are favorable for mosquito
reproduction
Medical prophylaxis
● There is no direct risk to the agricultural industry, however, if working individuals become
incapacitated due to YFV infection, they will not be able to perform the duties required of them. This
may have negative impacts on farms and livestock ranches.
● Alberta Health (2018). Yellow fever. Public Health Management Guidelines Accessed 2020:
https://open.alberta.ca/dataset/adfb8959-5a88-4b7c-a2f0-8cefb7dc6b09/resource/1afe9e80-9200-
482b-9e4a-d9af69aceeb0/download/guidelines-yellow-fever-2018-05.pdf
● Carrington, C. V. F., & Auguste, A. J. (2013). Evolutionary and ecological factors underlying the
tempo and distribution of yellow fever virus activity. Infection, Genetics, and Ecolution, 13, 198-210.
● Centers for Disease Control and Prevention (2019). Yellow fever: prevention. Accessed 2020:
https://www.cdc.gov/yellowfever/prevention/index.html
● Domingo, C., Charrel, R. N., Schmidt-Chanasit, J., Zeller, H., & Reusken, C. (2018). Yellow fever in
the diagnostics laboratory. Emerging Microbes and Infections, 7, 129.
● Fenner, F. J. (2011). Yellow fever virus. In N. J. MacLachlan and E. J. Dubovi (Eds.), Fenner's
Veterinary Virology (4th ed., p. 474). Elsevier.
● Jácome, R., Carrasco-Hernández, R., Campillo-Balderas, J. A., López-Vidal, Y., Lazcano, A., et al.
(2019). A yellow flag on the horizon: the looming threat of yellow fever to North America. International
Journal of Infectious Disease, 87, 143-150.
● Moreno, E. S., Spinola, R., Tengan, C. H., Brasil, R. A., et al. (2013). Yellow fever epizootics in non-
human primates, São Paulo State, Brazil, 2008-2009. Revista do Instituto de Medicina Tropical de
São Paulo, 55(1), 45-50.
● Public Health Agency of Canada (2010). Pathogen safety data sheets: infectious substances - yellow
fever virus. Accessed 2020: https://www.canada.ca/en/public-health/services/laboratory-biosafety-
biosecurity/pathogen-safety-data-sheets-risk-assessment/yellow-fever-virus.html
● Valentine, M. J., Murdock, C. C., & Kelly, P. J. (2019). Sylvatic cycles of arboviruses in non-human
primates. Parasites and Vectors, 12(1), 463.
● Wasserman, S., Tambyah, P., & Lim, P. L. (2016). Yellow fever cases in Asia: primed for an
epidemic. International Journal of Infectious Disease, 48, 98-103.
● Wermelinger, E. D. & de Carvalho, R. W. (2016). Methods and procedures used in Aedes aegypti
control in the successful campaign for yellow fever prophylaxis in Rio de Janeiro, Brazil, in 1928 and
1929. Epidemiologia e Serviços de Saúde, 25(4), 837-844.
● World Health Organisation (2019). Yellow fever. Accessed 2020: https://www.who.int/news-
room/fact-sheets/detail/yellow-fever
● Yuill, T. M. & Seymour, C. (2001). Yellow fever. In E. S. Williams and I. K. Barker (Eds.), Infectious
Diseases of WIld Mammals (3rd ed., pp. 98-100). Iowa State Press.
*
* *
The OIE will periodically update the OIE Technical Disease Cards. Please send relevant new references and
proposed modifications to the OIE Science Department (scientific.dept@oie.int). Last updated 2020. Written
by Samantha Gieger and Erin Furmaga with assistance from the USGS National Wildlife Health Center.